Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature review. (2nd July 2020)

• Record Type: Journal Article
• Authors: Yamaguchi, Yuta; Maeda, Yuichi; Shibahara, Takayuki; Nameki, Shinichiro; Nakabayashi, Akihiko; Komuta, Kiyohide; Mizuno, Yumiko; Yagita, Mayu; Manabe, Yusuke; Morita, Takayoshi; Nishide, Masayuki; Watanabe, Akane; Takamatsu, Hyota; Nishida, Sumiyuki; Hirano, Toru; Shima, Yoshihito; Narazaki, Masashi; Kumanogoh, Atsushi
• Is Part Of: Modern rheumatology case reports. Volume 4:Number 2(2020)
• Page Start: 302
• Page End: 309
• Publication Date: 2020-07-02
• Subjects: TAFRO syndrome -- thrombocytopenia -- megakaryocyte -- reticulin fibrosis -- literature review; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1080/24725625.2020.1717747
• Languages: English
• ISSNs: 2472-5625

Abstract

Abstract: TAFRO syndrome is a newly proposed disease that is characterised by thrombocytopenia, anasarca, fever, reticulin fibrosis (or renal dysfunction), and organomegaly. Generally, high doses of corticosteroids are recommended for the initial treatment of TAFRO syndrome; however, some patients experience prolonged refractory thrombocytopenia after initiating such therapies. If corticosteroid treatment alone is ineffective, additional immunosuppressive therapies such as cyclosporine A are recommended. Since long-term use of immunosuppressive therapies with TAFRO syndrome sometimes causes serious infection, it is important to recognise the time to recovery from thrombocytopenia. In this study, we investigated how long it took to recover from thrombocytopenia, to aid clinicians in decision-making regarding the need to strengthen treatment for prolonged thrombocytopenia. Here, we describe three of our patients with TAFRO syndrome exhibiting prolonged thrombocytopenia. We also investigated the median period to recovery from this complication (defined as the time to increase the platelet count above 50, 000/µL) after the initiation of high-dose corticosteroid treatment in our 3 cases and 38 peer-reviewed cases. We found that it took our patients 61 days to recover from thrombocytopenia; in comparison, our investigation of the 38 peer-reviewed case reports revealed a median recovery time of 47.5 days among previously reported patients. We showed the time to recovery from thrombocytopenia in patients with TAFRO syndrome for the first time. Our findings ought to be useful for decision-making among clinicians regarding the administration of other immunosuppressive treatments in addition to corticosteroid.